Pregabalin in Patients with Central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen.
Completed
- Conditions
- central neuropathic pain
- Registration Number
- NL-OMON26939
- Lead Sponsor
- Academic Medical Center, AmsterdamDepartment of anesthesiologyPain Relief Unit
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Age 18 years or older;
2. Written informed consent;
Exclusion Criteria
1. Pregnant;
2. Had a history of intolerance, hypersensitivity, or known allergy to pregabalin;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary efficacy parameter is a pain intensity score recorded by patients (at baseline, and 4 weeks following treatment), using a visual analog scale (VAS).
- Secondary Outcome Measures
Name Time Method Health status and quality of life (QOL) questionnaires (secondary outcomes) were completed before start of treatment and 4 weeks following start of treatment. Health status and QOL measurements included the Pain Disability Index (PDI), the EQ-5D, and the Medical Outcomes Short-form Health Survey questionnaire 36 (SF36).